KMTS
Fiscal year ends April Quarters are offset from the calendar — Q1 is May–Jul

Kestra Medical Technologies is a commercial-stage wearable medical device and digital healthcare company focused on cardiovascular disease. The company develops the Cardiac Recovery System platform, anchored by the ASSURE Wearable Cardioverter Defibrillator, which continuously monitors heart rhythms and delivers defibrillation therapy for life-threatening ventricular arrhythmias. The platform includes the ASSURE patient application, the Kestra CareStation remote patient management platform, Heart Alert Services, and ASSURE Assist to support patient engagement and clinical workflow. Kestra serves patients at elevated risk of sudden cardiac arrest who are not candidates for implantable cardioverter defibrillators, primarily in the United States, with plans to pursue CE Mark approval for Western Europe. Founded in 2014, the company received FDA approval for the ASSURE WCD in 2021.

Summarised from the company's own disclosures, fiscal year ended Jul 2026

Industry Medical Devices Homepage kestramedical.com
Sector Healthcare IR page investors.kestramedical.com
Tags
wearable cardioverter defibrillators, cardiac monitoring, remote patient management, sudden cardiac arrest prevention, digital health, ventricular arrhythmia therapy, ASSURE Wearable Cardioverter Defibrillator, Cardiac Recovery System, ASSURE patient application, Kestra CareStation, Heart Alert Services, ASSURE Assist
Press page —

Metrics

Valuation  
Market cap $ 1.752B
Market cap (USD) $ 1.752B
P/E -11.03
PEG —
P/BV 7.88
P/S 16.42
P/OCF -21.44
P/FCF -15.03
Dividend yield —
Turnover / mcap —
Returns  
ROE -56.6%
ROI -43.5%
ROIC -33.4%
Profit margin -138.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 32.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 17
Quality score -43.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2021
Revenue 95.126M 59.815M 27.814M 7.63M 0
Net profit -131.612M -113.814M -94.12M -84.238M -34.101M
Free cash flow -116.595M -100.544M -84.749M -85.103M -30.231M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2021
Share price 20.04 24.92 — — —
Price performance 12m -0.2 — — — —

Filed figures

Figure Apr 2023 Apr 2024 Apr 2025 Apr 2026
Balance sheet detail
Trade receivables (USD) — 2M 8.08M 14.5M
↳ YoY growth +304.5% +80.0%
Borrowings, non-current (USD) — 42.5M 41.1M 42.6M
Lease liabilities (USD) — 2.63M 3.21M 4.14M
Cash and deposits (USD) 15.3M 8.25M 238M 99.7M
Right-of-use assets (USD) — 2.29M 2.08M 3.36M
Net debt (borrowings + leases - cash) (USD) — 36.9M -193M -52.9M
Cash flow detail
Operating cash flow (USD) — -72.2M -77.6M -81.7M
Purchases of property, plant and equipment (USD) — -12.2M -22.9M -34.9M
Change in receivables (cash effect) (USD) — -2.5M -8.78M -9.06M
Change in payables (cash effect) (USD) — 7.34M 2.84M 4.3M
Interest paid (cash effect) (USD) — -3.63M -4.85M -5.65M
Income taxes paid (cash effect) (USD) — 30,000 -83,000 -13,000
Share-based compensation (USD) — 1.49M 24.3M 33.6M
Operating cash flow before change in receivables (USD) — -69.7M -68.8M -72.6M
Free cash flow (OCF - PPE - intangibles) (USD) — -84.5M -101M -117M
Income detail
Research and development expense (USD) — 15.5M 15.7M 19.5M
Total comprehensive income (USD) — — -114M -132M
Comprehensive income to owners (USD) — — -114M -132M
Reported Jul 17, 2025 Jul 17, 2025 Jul 14, 2026 Jul 14, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

October 30, 2026

PDF Version

KIRKLAND, Wash., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, is scheduled to participate in the following upcoming investor conferences:

Event: Wolfe Research Healthcare Conference 2026 Date: Tuesday, November 10 Presentation time: 2:40 p.m. ET

Event: Stifel Healthcare Conference 2026 Date: Wednesday, November 11 Presentation time: 2:00 p.m. ET

Event: Piper Sandler 38th Annual Healthcare Conference Date: Tuesday, December 1 Presentation time: 11:00 a.m. ET

Interested parties may access the live webcast and replay of each presentation by visiting the Kestra investor relations website.

About Kestra Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.

Investor contact Neil Bhalodkar [email protected]

Search Investors

October 1, 2026

PDF Version

KIRKLAND, Wash., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, has earned a five-star rating on Newsweek’s list of America’s Greatest Mid-Market Companies 2026. Only 30 of the 100 honorees earned five stars, and Kestra was the only company in the Medical Equipment Manufacturing category to receive that rating.

“In less than a decade, our team brought the ASSURE® WCD to market and built a rapidly growing commercial business, giving clinicians a differentiated choice for protecting patients during periods of cardiac risk and recovery,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “This five-star rating reflects the strength of the Kestra team and the company we’ve built. We’re now positioned to extend our reach, advance our Cardiac Recovery System® platform, and pursue a bigger vision for wearable cardiac protection.”

For its inaugural ranking, Newsweek and Plant-A Insights Group assessed publicly traded U.S. mid-market companies across financial performance, workforce experience, innovation, and sustainability. Their analysis drew on business metrics, third-party workforce data, and more than 2.7 million company reviews.

“Newsweek’s ranking of America’s Greatest Mid-Market Companies recognizes businesses that are proving that meaningful growth and lasting impact aren’t limited to the largest corporations,” added Ryan Kinney, Senior Vice President, Newsweek. “The ranking shines a spotlight on midsize companies that are strengthening their industries, creating opportunities for team members and customers, and demonstrating the ambition and resilience needed to succeed in a competitive marketplace.”

About Kestra Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.

Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied by these statements. For a discussion of factors that could cause actual results to differ, see Kestra's filings with the U.S. Securities and Exchange Commission. Kestra undertakes no obligation to update any forward-looking statements except as required by law.

Media contact Rhiannon Pickus [email protected]

Search Investors

September 14, 2026

PDF Version

KIRKLAND, Wash., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the first quarter of fiscal year 2027, which ended July 31, 2026.

Financial Highlights

  • Generated revenue of $31.0 million in F1Q27, an increase of 60% compared to the prior year period.

  • Expanded gross margin to 56.5% in F1Q27 compared to 45.7% in the prior year period.

  • Increased FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26.

“Kestra delivered another strong quarter of financial performance, generating revenue growth of 60% while expanding gross margin to over 56%,” said Brian Webster, President and CEO. “We remain confident that our focus on innovation and commercial expansion positions Kestra to generate durable, top-tier growth for years to come. Our team is executing on its commitments to prescribers and their patients and we believe this will continue to drive market expansion and advance Kestra on its path to market leadership.”

First Quarter Fiscal 2027 Financial Results

  • Total revenue was $31.0 million, an increase of 60% compared to the prior year period.

  • Revenue growth was driven by several factors, including wearable cardioverter defibrillator (WCD) market expansion, competitive share gains, new sales territories, higher mix of in-network patients, and ongoing improvements in revenue cycle management capabilities.

  • Gross profit was $17.5 million compared to $8.9 million in the prior year period.

  • Gross margin expanded to 56.5% compared to 45.7% in the prior year period, driven by volume leverage, a higher mix of in-network patients and execution of planned cost improvement programs.

  • GAAP operating expenses were $55.2 million compared to $37.7 million in the prior year period.

  • Excluding non-recurring costs and share-based compensation expense, adjusted operating expenses* were $44.2 million compared to $30.3 million in the prior year period. The increase was primarily attributable to growth in expenses related to the company’s commercial expansion and accelerated investment in key R&D programs.

  • GAAP net loss was $44.1 million compared to GAAP net loss of $25.8 million in the prior year period.

  • Adjusted EBITDA* loss was $24.0 million compared to an adjusted EBITDA loss of $19.4 million in the prior year period.

  • Cash and cash equivalents, and investments totaled $244.7 million as of July 31, 2026.

  • Including committed unused availability under the company’s term loan agreement, Kestra has total liquidity of approximately $320 million.

*Adjusted operating expenses and adjusted EBITDA are non-GAAP financial measures. See “Use of Non-GAAP Financial Measures” below for additional information. Reconciliations of adjusted operating expenses and adjusted EBITDA to the most directly comparable GAAP measure are included in this press release.

Fiscal Year 2027 Revenue Guidance Kestra is increasing its FY27 revenue guidance to $141 million, representing growth of 48% compared to FY26. This compares to prior FY27 revenue guidance of $137 million.

Webcast and Conference Call Kestra will host a conference call today at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the event will be available in the “Events” section of the investor relations website.

About Kestra Kestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, visit www.kestramedical.com.

Use of Non-GAAP Financial Measures This press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (“GAAP”), including adjusted operating expense and adjusted EBITDA. The non-GAAP financial measures are provided as supplemental information to Kestra’s financial measures presented in this press release that are calculated and presented in accordance with GAAP.

Adjusted operating expense is calculated as operating expenses, as adjusted to exclude share-based compensation expense and non-recurring expenses. Adjusted EBITDA is calculated as net income (loss), as adjusted to exclude other income/expense (including interest), income tax expense (benefit), depreciation and amortization expense, share-based compensation expense, and non-recurring expenses. Both metrics are presented because management believes they will allow investors to view Kestra’s performance in a manner similar to the method used by management to evaluate Kestra’s performance for both strategic and annual operating planning. Management believes that in order to properly understand short-term and long-term financial trends, it is helpful for investors to understand the impact of the items excluded from the calculation of adjusted operating expenses and adjusted EBITDA, in addition to considering Kestra’s GAAP financial measures. The excluded items vary in frequency and/or impact on our results of operations and management believes that the excluded items are not reflective of our ongoing core business operations and financial condition. Excluding such items allows investors and analysts to compare our operating performance to other companies in our industry and to compare our period-over-period results.

The non-GAAP financial measures used by Kestra may not be the same or calculated in the same manner as those used and calculated by other companies. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for Kestra’s financial results prepared and reported in accordance with GAAP. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business. A reconciliation of adjusted operating expenses and adjusted EBITDA reported in this press release to the most comparable respective GAAP measure for the respective periods appears in the tables captioned “Reconciliation of GAAP Operating Expenses to Adjusted Operating Expenses” and “Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA” later in this release. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers.

Forward-Looking Statements Except where otherwise noted, the information contained in this press release is as of September 14, 2026. Statements in this press release and on the related teleconference that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. Except as required by law, Kestra undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; business plans, strategy, goals and prospects, potential growth, and expectations for our products. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions, and we cannot ensure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “continue,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “advance,” “remain,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope” and other words and terms of similar meaning. Kestra’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following: risks related to our limited operating history and history of net losses; our ability to successfully achieve substantial market adoption of our products; competitive pressures; our ability to adapt our manufacturing and production capacities to evolving patterns of demand, governmental actions and customer trends; product defects or complaints and related liability; our ability to obtain and maintain adequate coverage and reimbursement levels for our products; our ability to comply with changing laws and regulatory requirements and resulting costs; our dependence on a limited number of suppliers; risks and uncertainties related to market conditions; and other risks and uncertainties, including those described under the heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended April 30, 2026 and other filings filed or to be filed with the U.S. Securities and Exchange Commission (“SEC”). These filings, when made, are available on the Investor Relations section of our website at https://investors.kestramedical.com/ and on the SEC’s website at https://sec.gov/.

| KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share amounts) (unaudited) |

| | | Three Months Ended July 31, | |

| | | 2026 | | | 2025 | |

| | | | | | | |

| Revenue | | $ | 30,971 | | | $ | 19,371 | |

| Cost of revenue | | | 13,473 | | | | 10,520 | |

| Gross profit | | | 17,498 | | | | 8,851 | |

| Operating expenses: | | | | | | |

| Research and development | | | 6,796 | | | | 4,001 | |

| Selling, general and administrative | | | 48,359 | | | | 33,728 | |

| Total operating expenses | | | 55,155 | | | | 37,729 | |

| Loss from operations | | | (37,657 | ) | | | (28,878 | ) |

| Other expense (income): | | | | | | |

| Interest expense | | | 1,929 | | | | 1,912 | |

| Interest income | | | (2,125 | ) | | | (2,167 | ) |

| Other expense (income), net | | | 272 | | | | (2,830 | ) |

| Loss on extinguishment of debt | | | 6,304 | | | | — | |

| Net loss before provision for income taxes | | | (44,037 | ) | | | (25,793 | ) |

| Provision for income taxes | | | 50 | | | | 33 | |

| Net loss attributable to common shareholders, basic and diluted | | $ | (44,087 | ) | | $ | (25,826 | ) |

| | | | | | | |

| Net loss per share attributable to common shareholders, basic and diluted | | $ | (0.75 | ) | | $ | (0.50 | ) |

| Weighted-average common shares outstanding, basic and diluted | | | 58,566,467 | | | | 51,304,599 | |

| | | | | | | |

| Other comprehensive loss: | | | | | | |

| Net loss | | $ | (44,087 | ) | | $ | (25,826 | ) |

| Unrealized loss on marketable securities | | | (253 | ) | | — | |

| Comprehensive loss | | $ | (44,340 | ) | | $ | (25,826 | ) |

| KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) (unaudited) |

| | | July 31, | | | April 30, | |

| | | 2026 | | | 2026 | |

| | | | | | | |

| Assets | | | | | | |

| Current assets | | | | | | |

| Cash and cash equivalents | | $ | 68,558 | | | $ | 99,710 | |

| Short-term investments | | | 130,353 | | | $ | 96,724 | |

| Accounts receivable, net | | | 15,406 | | | | 14,542 | |

| Disposable medical equipment supplies | | | 7,438 | | | | 6,706 | |

| Prepaid expenses and other current assets | | | 4,518 | | | | 4,677 | |

| Total current assets | | | 226,273 | | | | 222,359 | |

| | | | | | | |

| Long-term investments | | | 45,791 | | | | 65,767 | |

| Right-of-use assets | | | 3,263 | | | | 3,364 | |

| Deposits | | | 1,842 | | | | 1,761 | |

| Restricted cash | | | 334 | | | | 334 | |

| Property and equipment, net | | | 63,656 | | | | 59,090 | |

| Other long-term assets | | | 6,196 | | | | 5,790 | |

| Total assets | | $ | 347,355 | | | $ | 358,465 | |

| | | | | | | |

| Liabilities and Shareholders’ Equity | | | | | | |

| Current liabilities | | | | | | |

| Accounts payable | | $ | 25,961 | | | $ | 27,295 | |

| Accrued liabilities | | | 22,285 | | | | 23,046 | |

| Operating lease liabilities, current portion | | | 23 | | | | 31 | |

| Total current liabilities | | | 48,269 | | | | 50,372 | |

| | | | | | | |

| Operating lease liabilities, net of current portion | | | 3,928 | | | | 4,111 | |

| Warrant liabilities | | — | | | | 1,369 | |

| Other long-term liabilities | | | 306 | | | | 306 | |

| Long-term debt, net | | | 72,495 | | | | 42,649 | |

| Total liabilities | | | 124,998 | | | | 98,807 | |

| | | | | | | |

| Commitments and contingencies | | | | | | |

| | | | | | | |

| Shareholders’ equity | | | | | | |

| | | | | | | |

| Common Shares, $1.00 par value; 100,000,000 shares authorized as of July 31, 2026 and April 30, 2026; 59,271,885 issued and outstanding as of July 31, 2026 and 58,383,924 shares issued and outstanding as of April 30, 2026 | | | 59,272 | | | | 58,384 | |

| Additional paid-in capital | | | 859,504 | | | | 853,353 | |

| Accumulated other comprehensive loss | | | (471 | ) | | | (218 | ) |

| Accumulated deficit | | | (695,948 | ) | | | (651,861 | ) |

| Total shareholders’ equity | | | 222,357 | | | | 259,658 | |

| Total liabilities and shareholders’ equity | | $ | 347,355 | | | $ | 358,465 | |

| KESTRA MEDICAL TECHNOLOGIES, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) |

| | | Three Months Ended July 31, | |

| | | 2026 | | | 2025 | |

| Cash flows from operating activities | | | | | | |

| Net loss | | $ | (44,087 | ) | | $ | (25,826 | ) |

| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | |

| Depreciation and amortization | | | 2,664 | | | | 2,028 | |

| Loss on disposal of property and equipment | | | 292 | | | | 280 | |

| Reserve for equipment and supplies | | | 1,464 | | | | 412 | |

| (Recovery) provision for uncollectible accounts receivable | | | (817 | ) | | | 613 | |

| Amortization (accretion) of premiums (discounts) on securities, net | | | (890 | ) | | — | |

| Loss on extinguishment of debt | | | 6,304 | | | — | |

| Amortization of debt discounts and issuance costs | | | 408 | | | | 469 | |

| Share-based compensation expense | | | 9,517 | | | | 4,579 | |

| Non-cash lease expense | | | 103 | | | | 61 | |

| Change in fair value of warrant liabilities | | | 251 | | | | (2,909 | ) |

| Changes in operating assets and liabilities: | | | | | | |

| Disposable medical equipment supplies | | | (908 | ) | | | (460 | ) |

| Prepaid expenses and other current assets | | | 246 | | | | 140 | |

| Accounts receivable | | | (48 | ) | | | (1,777 | ) |

| Accounts payable | | | (1,879 | ) | | | (2,896 | ) |

| Accrued liabilities | | | (4,727 | ) | | | (860 | ) |

| Operating lease liabilities | | | (190 | ) | | | (138 | ) |

| Other long-term assets | | | 2 | | | | 10 | |

| Net cash used in operating activities | | | (32,295 | ) | | | (26,274 | ) |

| Cash flows from investing activities | | | | | | |

| Purchases of property and equipment | | | (8,335 | ) | | | (8,166 | ) |

| Deposits for medical rental equipment | | — | | | | (103 | ) |

| Refund of deposits for medical rental equipment | | — | | | | 37 | |

| Purchase of marketable securities | | | (13,017 | ) | | | — | |

| Net cash used in investing activities | | | (21,352 | ) | | | (8,232 | ) |

| Cash flows from financing activities | | | | | | |

| Proceeds from issuance of long-term debt | | | 75,000 | | | — | |

| Payment of debt issuance costs | | | (3,193 | ) | | — | |

| Repayment of long-term debt | | | (46,395 | ) | | — | |

| Payment of early termination fee on debt repayment | | | (3,758 | ) | | | |

| Payment of IPO offering costs | | | — | | | | (1,875 | ) |

| Payment of equity issuance costs | | | (415 | ) | | — | |

| Deemed dividend for payments to third party on behalf of shareholder | | | (172 | ) | | — | |

| Proceeds from stock option exercises | | | 1,140 | | | — | |

| Proceeds from Employee Stock Purchase Plan | | | 1,298 | | | — | |

| Tax withholdings on restricted stock unit vesting | | | (1,010 | ) | | — | |

| Net cash provided by (used in) financing activities | | | 22,495 | | | | (1,875 | ) |

| Net decrease in cash, cash equivalents and restricted cash | | | (31,152 | ) | | | (36,381 | ) |

| Cash, cash equivalents and restricted cash | | | | | | |

| Beginning of period | | | 100,044 | | | | 237,929 | |

| End of period | | $ | 68,892 | | | $ | 201,548 | |

| RECONCILIATION OF CASH AND CASH EQUIVALENTS TO CASH, CASH EQUIVALENTS, AND INVESTMENTS (in thousands) (unaudited) |

| | | Three Months Ended July 31, | |

| | | 2026 | | | 2025 | |

| Cash and cash equivalents | | $ | 68,558 | | | $ | 201,214 | |

| Add: Short-term investments | | | 130,353 | | | — | |

| Add: Long-term investments | | | 45,791 | | | — | |

| Cash, cash equivalents, and investments | | $ | 244,702 | | | $ | 201,214 | |

| RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (in thousands) (unaudited) |

| | | Three Months Ended July 31, | |

| | | 2026 | | | 2025 | |

| | | | | | | |

| GAAP Net loss | | $ | (44,087 | ) | | $ | (25,826 | ) |

| Non-GAAP Adjustments: | | | | | | |

| Interest expense | | | 1,929 | | | | 1,912 | |

| Interest income | | | (2,125 | ) | | | (2,167 | ) |

| Other expense (income) | | | 272 | | | | (2,830 | ) |

| Provision for income taxes | | | 50 | | | | 33 | |

| Depreciation expense | | | 2,664 | | | | 2,028 | |

| Share-based compensation expense | | | 9,517 | | | | 4,579 | |

| Loss on extinguishment of debt | | | 6,304 | | | | — | |

| Non-recurring expenses | | | 1,430 | | | | 2,866 | |

| Adjusted EBITDA | | $ | (24,046 | ) | | $ | (19,405 | ) |

| RECONCILIATION OF GAAP OPERATING EXPENSES TO ADJUSTED OPERATING EXPENSES (in thousands) (unaudited) |

| | | Three Months Ended July 31, | |

| | | 2026 | | | 2025 | |

| | | | | | | |

| GAAP Operating Expenses | | $ | 55,155 | | | $ | 37,729 | |

| Non-GAAP Adjustments: | | | | | | |

| Share-based compensation expense | | | 9,517 | | | | 4,579 | |

| Non-recurring expenses | | | 1,430 | | | | 2,866 | |

| Adjusted Operating Expenses | | $ | 44,208 | | | $ | 30,284 | |

Investor Relations Neil Bhalodkar [email protected]

Search Investors

Prompts

Kestra Medical Technologies, Ltd. (ticker KMTS), listed in United States.

ETFs Holding Kestra Medical Technologies, Ltd.

ETF Weight in ETF Shares Market value As of
FMED 1.10% 22,000 $ 566.5K Aug 31, 2026
ESSC 0.12% 1,934 $ 44.153K Jul 31, 2026
ORR short -0.12% -16,093 $ -450K Nov 18, 2026
TMSL 0.10% 110,315 $ 2.806M Jun 30, 2026
FBCG 0.04% 112,522 $ 2.569M Jul 31, 2026